Assessment of QTc interval prolongation in a phase I study using monte carlo simulation

Simulation for Designing Clinical Trials: A Pharmacokinetic-Pharmacodynamic Modeling Perspective

Volumn , Issue , 2002, Pages 353-368

  Bonate, Peter L ^a,b  

^a IQVIA   (United States)

^b Ilex Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646661455     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (19)

1. PL Bonate, T Russell. Assessment of QTc prolongation for non-cardiac drugs from a drug development perspective. J Clin Pharmacol 39:349-358, 1999.
2. S Ahnve. Correction of the QT interval for heart rate: review of different formulas and the use of Bazett’s formula in myocardial infarction. Am Heart J 109:568-574, 1985.
3. C Funck-Bretano, P Jaillon. Rate-corrected QT interval: techniques and limitations. Am J Cardiol 72:17B-22B, 1993.
4. European Agency for the Evaluation of Medicinal Products (EMEA): Committee for Proprietary Medicinal Products (CPMP). Points to Consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products, London, 17 December 1997. CPMP/986/96.
5. AJ Moss. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 72:23B-25B, 1993.
6. D Nagy, R DeMeersman, D Gallagher, A Pietrobelli, AS Zion, D Daly, SB Heyms-field. QTc Interval (cardiac repolarization): lengthening after meals. Obesity Res 5: 531-537, 1997.
7. DM Mirvis. Spatial variation of QT intervals in normal persons and patients with myocardial infarction. J Am Coll Cardiol 5:625-631, 1985.
8. RS Bexton, HO Vallin, AJ Camm. Diurnal variation of the QT interval—influence of the autonomic nervous system. Br Heart J 55:253-258, 1986.
9. HC Bazett. An analysis of time-relations of electrocardiograms. Heart 7:353-370, 1920.
10. EA Gehan, SL George. Estimation of human body surface area from height and weight. Cancer Chem Rep 54:225-235, 1970.
11. EI Ette, TM Ludden. Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res 12:1845-1855, 1995.
12. R Bruno, N Vivier, JC Vergniol, SL De Phillips, G Montay, LB Shiener. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokin Biopharm 24:153-172, 1996.
13. JR Wade, SL Beal, NC Sambol. Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis. J Pharmacokin Biopharm 22: 165-177, 1994.
14. EI Ette. Comparing non-hierarchical models: application to non-linear mixed effects modeling. Comp Biol Med 6:505-512, 1996.
15. RL Iman, JC Helton, JE Campbell. An approach to sensitivity analysis of computer models: part II—ranking of input variables, response surface validation, distribution effect, and technique synopsis. J Qual Technol 13:232-240, 1981.
16. DJ Downing, RH Gardner, FO Hoffman. An examination of response surface methodologies for uncertainty analysis in assessment models. Technometrics 27:151-163, 1985.
17. PL Bonate. The effect of collinearity on parameter estimates in nonlinear mixed effect models. Pharm Res 16:709-717, 1999.
18. J Morganroth, AM Brown, S Critz, WJ Crumb, DL Kunze, AE Lacerda, H Lopez. Variability of the QTc interval: impact on defining drug effect and low-frequency cardiac event. Am J Cardiol 72:26B-31B, 1993.
19. J Morganroth, FV Brozovich, JT McDonald, RA Jacobs. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 67:774-776, 1991.